Skip to content
10-Q

Quarterly Report

VERTEX PHARMACEUTICALS INC / MA VRTX

0000875320-25-000192

← back to feed
Filed
May 6, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Apr 30, 2025 256.8M sh
Current Liabilities Q1 2025 · Mar 31, 2025 $3.78B
Current Liabilities Q1 2025 · Dec 31, 2024 $3.56B
Total Liabilities Q1 2025 · Mar 31, 2025 $6.38B
Total Liabilities Q1 2025 · Dec 31, 2024 $6.12B
Current Assets Q1 2025 · Mar 31, 2025 $10.01B
Current Assets Q1 2025 · Dec 31, 2024 $9.6B
Total Assets Q1 2025 · Mar 31, 2025 $22.88B
Total Assets Q1 2025 · Dec 31, 2024 $22.53B
Shares Diluted Q1 2025 · Mar 31, 2024 261.1M sh
Stock Repurchased Q1 2025 · Mar 31, 2024 $131.2M
Capex Q1 2025 · Mar 31, 2024 $68.4M
Operating Cash Flow Q1 2025 · Mar 31, 2024 $1.31B
Cash And Equivalents Q1 2025 · Mar 31, 2024 $9.16B
Cash And Equivalents Q1 2025 · Dec 31, 2023 $10.37B
Stockholders Equity Q1 2025 · Mar 31, 2024 $18.55B
Stockholders Equity Q1 2025 · Dec 31, 2023 $17.58B
Eps Diluted Q1 2025 · Mar 31, 2024 $4.21
Eps Basic Q1 2025 · Mar 31, 2024 $4.26
Sga Expense Q1 2025 · Mar 31, 2024 $342.7M
Net Income Q1 2025 · Mar 31, 2024 $1.1B
Operating Income Q1 2025 · Mar 31, 2024 $1.14B
Cost Of Revenue Q1 2025 · Mar 31, 2024 $342.6M
Revenue Q1 2025 · Mar 31, 2024 $2.69B